Division of WuXi PharmaTech Inc.
Latest From WuXi Biologics
OvaScience’s cash plus a $49.5m venture capital raise leave Millendo with more than enough to get two current programs to data readouts in early 2020, company says. AMAG merges with Perosphere, adding to its hematology business.
China-focused Brii Biosciences, formed earlier this year, unveils plans to take its first projects into the clinic by way of deals with VBI and Vir for hepatitis B, and builds other alliances and operations in the country.
The pharma, biotech and allied industries came together to celebrate another year of excellence at the 14th Annual Scrip awards in London on Nov. 28, hosted by the Right Honourable Lord (William) Hague.
Agreement between FujiFilm and Hisun sets plan for developing the novel flu drug Avigan in China. Also, CANbridge and WuXi partner in rare diseases, and Kissei gets Asian rights to Rigel’s Tavalisse.
- Large Molecule
- Contract Research, Toxicology Testing-CRO
- Therapeutic Areas
- Parent & Subsidiaries
- WuXi PharmaTech Inc.
- Senior Management
Chris Chen, PhD, CEO
Weichang Zhou, PhD, CTO
- Contact Info
Phone: 400 820 0985
288 Fute Zhong Rd.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.